Literature DB >> 1125521

Observations on the dose regime of fluphenazine decanoate in maintenance therapy ofschizophrenia.

D A Johnson.   

Abstract

An analysis of the drug regimes prescribed to two separate groups of unselected schizophrenic patients indicates certain trends of clinical importance. The results demonstrate a need for the adoption of a personalized dose regime. The scatter of dose regimes found effective is too great to recommend a standardized approach to the prescription of L.A.P. injections. Two other results of particular significance are that the dose of drug required to control symptoms can be gradually reduced in nearly half of patients,and that helpful trends in prescribing were identified that will help the clinician to abolish side-effects.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1125521     DOI: 10.1192/bjp.126.5.457

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  6 in total

1.  Assessment of drugs in schizophrenia. Discussion on assessment of drug-induced extrapyramidal reactions.

Authors:  H A McClelland
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

Review 2.  Pharmacological treatment of patients with schizophrenia. Past and present problems and potential future therapy.

Authors:  D A Johnson
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

Review 3.  Review: treatment of schizophrenia. State of the art.

Authors:  H J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

4.  Treatment of chronic schizophrenia.

Authors:  D A Johnson
Journal:  Drugs       Date:  1977-10       Impact factor: 9.546

Review 5.  Clinically significant interactions of psychotropic agents with antipsychotic drugs.

Authors:  M C Meyer; R J Baldessarini; D C Goff; F Centorrino
Journal:  Drug Saf       Date:  1996-11       Impact factor: 5.606

6.  Assessment of drugs in schizophrenia. Diagnosis and patient selection.

Authors:  A D Forrest
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.